Lozano Borregón, DanielRodríguez de Gortázar Alonso-Villalobos, María ArántzazuPortal Núñez, SergioUniversidad San Pablo-CEU. Escuela Politécnica SuperiorGrupo: Fisiopatología ósea (FPO)2024-04-112024-04-112024-03-27Daniel Lozano, Arancha R. Gortazar, Sergio Portal-Núñez, Osteostatin, a peptide for the future treatment of musculoskeletal diseases, Biochemical Pharmacology, Volume 223, 2024, 116177, ISSN 0006-2952, https://doi.org/10.1016/j.bcp.2024.1161771873-2968http://hdl.handle.net/10637/15729Nowadays, the treatment of musculoskeletal diseases represents a major challenge in the developed world. Diseases such as osteoporosis, osteoarthritis and arthritis have a high incidence and prevalence as a consequence of population aging, and they are also associated with a socioeconomic burden. Many efforts have been made to find a treatment for these diseases with various levels of success, but new approaches are still needed to deal with these pathologies. In this context, one peptide derived for the C-terminal extreme of the Parathormone related Peptide (PTHrP) called Osteostatin can be useful to treat musculoskeletal diseases. This pentapeptide (TRSAW) has demonstrated both in different in vitro and in vivo models, its role as a molecule with anti-resorptive, anabolic, anti-inflammatory, and anti-antioxidant properties. Our aim with this work is to review the Osteostatin main features, the knowledge of its mechanisms of action as well as its possible use for the treatment of osteoporosis, bone regeneration and fractures and against arthritis given its anti-inflammatory properties.application/pdfenopen accessBoneOsteoporosisFractures.AgingOsteostatinArtículo10.1016/j.bcp.2024.116177https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es